Cognition Therapeutics (CGTX) Other Non Operating Income (2020 - 2026)

Cognition Therapeutics (CGTX) has reported Other Non Operating Income for 7 consecutive years, with $273000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non Operating Income fell 94.84% year-over-year to $273000.0; the TTM figure through Mar 2026 stood at -$11.2 million (down 185.97% YoY), while the FY2025 annual figure was $919000.0, down 95.4% from the prior year.
• Other Non Operating Income improved to $273000.0 in Q1 2026 per CGTX's latest filing, from -$13.1 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $12.2 million in Q4 2022 and bottomed at -$13.1 million in Q4 2025.
• Historically, Other Non Operating Income has averaged $2.8 million across 5 years, with a median of $2.8 million in 2023.
• On a YoY basis, Other Non Operating Income climbed as much as 2070.08% in 2025 and fell as far as 553.49% in 2025.
• Cognition Therapeutics' Other Non Operating Income stood at $12.2 million in 2022, then slumped by 42.38% to $7.0 million in 2023, then tumbled by 59.12% to $2.9 million in 2024, then slumped by 553.49% to -$13.1 million in 2025, then surged by 102.09% to $273000.0 in 2026.
• Business Quant data shows CGTX's Other Non Operating Income at $273000.0 in Q1 2026, -$13.1 million in Q4 2025, and $1.4 million in Q3 2025.